Table 6:
Systemic agents alone for FA-HNSCC Primaries
| Patient | Age | Sex | FA Group | SCT (Age) | Tumor site (subsite) | Stage | Surgical Resection | Systemic Agents (Dose) | Toxicities | Interruption or Termination of CT | Outcome | Recurrence | Second Primary |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anak #5 (2020)106 | 25 | M | - | Yes | Esophagus (cervical) | T3N1M0 | Yes | Cisplatin (30–40 mg/m^2) every 21 days, 5-FU (1 g/m^2 per cycle) | Mucositis, pancytopenia, sepsis | Yes (terminated) | DOD (6 mo pD) | Yes | - |
| Lach #1 (2020)48 | 51 | M | A | No | Esophagus (distal) | NA | Yes (salvage after CT) | Carboplatin and paclitaxel x1 cycle (dose NA, “low”) | Pancytopenia | Yes (terminated) | DOD (<1 yr pD) | Yes* [Table 7] | - |
| Beckham #4 (2019)65 | 32.6 | F | - | No | Esophagus (cervical) | T2N0 | No | Carboplatin and paclitaxel x2 cycles (dose NA) | Pancytopenia, liver failure, C. difficile colitis | Yes (terminated) | DOD (18 mo pD) | - | - |
| Masserot #3 (2008)64 | 17.5 | M | - | Yes (9.7) | Pharynx (hypopharynx) | T4N2cMX | No | Cisplatin (8 mg), 5-FU (60 mg) | NA | NA | DOD (6 mo pD) | - | - |
| Murayama 1990124 | 11 | M | - | Yes (8) | Oral cavity (dorsum of tongue) | NA | No | 5-FU (dose NA), cis-retinoic acid | NA | NA | DOD (3 mo pCT) | - | - |
| Fukuoka 1989125 | 39 | F | - | NA | Pharynx (pyriform sinus) | NA | No | Pepleomycin (dose NA) | NA | Yes (terminated) | DOD (NA) | - | - |
| Koo 1996105 | 44 | F | - | NA | Oral cavity | NA | No | Cis-retinoic acid (dose NA) | NA | NA | NA | Yes | - |
| Jung 2005107 | 27 | F | - | No | Oral cavity (tongue) | IVA | No | Gefitinib 250 mg/day, 2 month total duration | Well tolerated | No | DOD (from hepatocellular carcinoma, 2 mo pCT) | - | Liver, anal |